|
Apotex
Launches Gabapentin Capsules
Weston,
FL (April 6, 2005) — Apotex Corp. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for gabapentin capsules in 100mg, 300mg and 400mg dosage strengths. Shipments of the drug will commence immediately.
Gabapentin is the generic equivalent of Pfizer’s Neurontin®, used to treat epileptic seizures. Annual sales for gabapentin 100mg, 300mg and 400mg capsules in the U.S. are approximately $1.6 billion.
Apotex’ gabapentin capsules are packaged in bottles of 100s for all strengths, 500s for the 400mg strength and 1000s for the 100mg and 300mg strengths.
The Apotex Group manufactures more than 50 different high-quality generic pharmaceuticals, used by millions of patients worldwide. Its product line includes oral solids, liquids, injectables, nasal sprays, ophthalmics and inhalation solutions.
Neurontin® is a registered trademark of Warner-Lambert Company, a unit of Pfizer Inc.
About Apotex Corp.
Apotex Corp. is the U.S. subsidiary of Apotex Inc., the largest Canadian-owned manufacturer of prescription drugs. Through its sales and marketing headquarters in Weston, Florida, operations center in Indianapolis, and research facility in Lincolnshire, Illinois, Apotex Corp. is committed to providing safe and affordable generic medicines. Products manufactured and marketed by the Apotex Group are sold in 115 countries around the world. For more information visit
apotexcorp.com.
# # #
|
